Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933826 · ClinicalTrials.gov registry record
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
A clinical trial of Bladder Cancer and Non-muscle Invasive Bladder Cancer, sponsored by University of Washington.
- Active
- Registry status
- 570
- Enrollment target
- 20
- Study locations
NCT03933826 is a study of Bladder Cancer and Non-muscle Invasive Bladder Cancer that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 570 participants, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT03933826, a study of Bladder Cancer and Non-muscle Invasive Bladder Cancer, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- 570 participants
- Enrollment target
- 20
- Study locations
Study Summary
Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to fill these critical evidence gaps, change care pathways for the management of non-muscle-invasive bladder cancer (NMIBC), and provide for personalized, patient-centered care. The purpose of CISTO is to conduct a large prospective study that directly compares the impact of medical management versus bladder removal in recurrent high-grade NMIBC patients with Bacillus Calmette-Guerin (BCG) failure on clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).
Conditions Studied
Study Locations (20)
California
- USC/Norris Comprehensive CA Center - Los Angeles
- UCLA - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
Michigan
- Michigan Medicine Rogel Cancer Center - Ann Arbor
- Spectrum Health - Grand Rapids
- Comprehensive Urology -- A Division of Michigan Healthcare Professionals - Royal Oak
Florida
- University of Miami - Miami
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Maryland
- Johns Hopkins University, School of Medicine - Baltimore
- Chesapeake Urology Research Associates - Hanover
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Cancer Center - Phoenix
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 570 participants |
| Start Date | 2019-07-09 |
| Est. Completion | 2029-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03933826
The ClinicalTrials.gov registry entry for NCT03933826 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 570 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03933826 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Michigan, Florida.
Frequently Asked Questions
What is clinical trial NCT03933826 about?
NCT03933826 is a clinical study titled "CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer". Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinici...
What is the current status of trial NCT03933826?
This trial is currently active not recruiting. The enrollment target is 570 participants. The study started on 2019-07-09. Estimated completion is 2029-06-30.
What conditions does trial NCT03933826 study?
This clinical trial studies the following conditions: Bladder Cancer, Non-muscle Invasive Bladder Cancer, Cancer of the Bladder, Recurrent.
Who is sponsoring clinical trial NCT03933826?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03933826 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.